Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-cash Items (2021 - 2025)

Amylyx Pharmaceuticals has reported Non-cash Items over the past 5 years, most recently at $43.0 million for Q4 2025.

  • Quarterly results put Non-cash Items at $43.0 million for Q4 2025, up 1098.86% from a year ago — trailing twelve months through Dec 2025 was $43.0 million (up 1098.86% YoY), and the annual figure for FY2025 was $43.0 million, up 1098.86%.
  • Non-cash Items for Q4 2025 was $43.0 million at Amylyx Pharmaceuticals, up from $5.1 million in the prior quarter.
  • Over the last five years, Non-cash Items for AMLX hit a ceiling of $201.8 million in Q4 2022 and a floor of $287000.0 in Q2 2024.
  • Median Non-cash Items over the past 5 years was $3.9 million (2024), compared with a mean of $24.2 million.
  • Biggest five-year swings in Non-cash Items: tumbled 92.82% in 2023 and later soared 4735.89% in 2025.
  • Amylyx Pharmaceuticals' Non-cash Items stood at $15.6 million in 2021, then soared by 1191.13% to $201.8 million in 2022, then tumbled by 86.3% to $27.6 million in 2023, then crashed by 87.03% to $3.6 million in 2024, then surged by 1098.86% to $43.0 million in 2025.
  • The last three reported values for Non-cash Items were $43.0 million (Q4 2025), $5.1 million (Q3 2025), and $13.9 million (Q2 2025) per Business Quant data.